GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating restated by research analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Wednesday, Digital Look reports. They currently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft's price objective would suggest a potential upside of 6.87% from the company's current price.
Several other equities analysts have also weighed in on GSK. Citigroup cut their target price on GSK from GBX 2,250 to GBX 2,100 and set a "neutral" rating on the stock in a report on Wednesday, May 6th. Jefferies Financial Group reissued a "buy" rating and set a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, GSK has an average rating of "Hold" and a consensus price target of GBX 2,048.57.
Read Our Latest Report on GSK
GSK Price Performance
GSK stock opened at GBX 1,871.50 on Wednesday. The company has a market capitalization of £74.97 billion, a P/E ratio of 15.89, a P/E/G ratio of 1.24 and a beta of 0.29. The firm's fifty day simple moving average is GBX 1,927.12 and its 200-day simple moving average is GBX 1,988.25. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK has a 1-year low of GBX 1,444.50 and a 1-year high of GBX 2,282.
GSK (LON:GSK - Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Sell-side analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, insider Jonathan Symonds bought 1,550 shares of the company's stock in a transaction that occurred on Friday, June 19th. The shares were purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Also, insider Jeannie Lee bought 802 shares of the business's stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, with a total value of £40,653.38. In the last three months, insiders bought 3,618 shares of company stock valued at $13,481,942. Company insiders own 0.20% of the company's stock.
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.